ConductScience.org, home

Paper39652186

Cellular and molecular aspects of drug resistance in cancers.

Shaik R and 10 others. Daru, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Cellular and molecular aspects of drug resistance in cancers. Papers, record 39652186. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39652186

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cellular and molecular aspects of drug resistance in cancers.
PubMed
Journal
Daru
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.61, provisional
iCite
Revised in PubMed
2025-12-10
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shaik RRahaman
2Malik MSM Shaheer
3Basavaraju SSreevani
4Qurban JJihan
5Al-Subhi FMMFatimah M M
6Badampudi SSathvika
7Peddapaka JJagruthi
8Shaik AAzeeza
9Abd-El-Aziz AAhmad
10Moussa ZZiad
11Ahmed SASaleh Ahttps://orcid.org/0000-0002-2364-0380

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Drug Resistance, NeoplasmMajor topic
NeoplasmsMajor topic
Animals
Humans
Tumor Microenvironment

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
G00004605College of Humanities and Social Sciences, United Arab Emirates UniversityPubMed

Source PubMed

Download CSV of grants

References182

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129455643Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Mol Cancer2018https://conductscience.org/library/papers/29455643PubMed
237008473ABC transporters linked to multiple herbicide resistance in blackgrass (Alopecurus myosuroides).Front Plant Sci2023https://conductscience.org/library/papers/37008473PubMed
321622723Cancer stem cells and chemosensitivity.Clin Cancer Res2011https://conductscience.org/library/papers/21622723PubMed
435026309Platinum-based systematic therapy in triple-negative breast cancer.Biochim Biophys Acta Rev Cancer2022https://conductscience.org/library/papers/35026309PubMed
519583429ABC efflux pump-based resistance to chemotherapy drugs.Chem Rev2009https://conductscience.org/library/papers/19583429PubMed
621318221Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review).Int J Oncol2011https://conductscience.org/library/papers/21318221PubMed
720360931Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.Transl Oncol2010https://conductscience.org/library/papers/20360931PubMed
833596421An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.Cell Rep2021https://conductscience.org/library/papers/33596421PubMed
930686761Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.Trends Mol Med2019https://conductscience.org/library/papers/30686761PubMed
1034488605Glimpse into the Cellular Internalization and Intracellular Trafficking of Lipid- Based Nanoparticles in Cancer Cells.Anticancer Agents Med Chem2022https://conductscience.org/library/papers/34488605PubMed
1128529100Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA.Genomics Proteomics Bioinformatics2017https://conductscience.org/library/papers/28529100PubMed
1221088257Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.Clin Cancer Res2011https://conductscience.org/library/papers/21088257PubMed
1337047688Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.Int J Mol Sci2023https://conductscience.org/library/papers/37047688PubMed
14325360125-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes.Cancer Sci2020https://conductscience.org/library/papers/32536012PubMed
1522436374Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.BMC Med2012https://conductscience.org/library/papers/22436374PubMed
1623435357Molecular aspects of cancer cell resistance to chemotherapy.Biochem Pharmacol2013https://conductscience.org/library/papers/23435357PubMed
1720684746Metabolism considerations for kinase inhibitors in cancer treatment.Expert Opin Drug Metab Toxicol2010https://conductscience.org/library/papers/20684746PubMed
1820045055Enabling individualized therapy through nanotechnology.Pharmacol Res2010https://conductscience.org/library/papers/20045055PubMed
1925621458Large multiallelic copy number variations in humans.Nat Genet2015https://conductscience.org/library/papers/25621458PubMed
2037931371Epigenetic modifications: Key players in cancer heterogeneity and drug resistance.Transl Oncol2024https://conductscience.org/library/papers/37931371PubMed

See all 182 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42467388Cancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targets.Mol Biomed2026https://conductscience.org/library/papers/42467388PubMed
41078404Current Advances in Nanocarriers for Cancer Therapy.Int J Nanomedicine2025https://conductscience.org/library/papers/41078404PubMed
40265428In Vitro Study on the Antitumor Bioactivity of Anderson-Type Polyoxometalates.Curr Pharm Des2025https://conductscience.org/library/papers/40265428PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PGP283871PubTator's text mininghttps://conductscience.org/library/genes/283871

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39652186

GET https://conductscience.org/api/papers/v1/39652186/references?page=2